We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




RF Device Detects Breast Cancer Margins During Surgery

By HospiMedica International staff writers
Posted on 12 Nov 2008
A novel detection system characterizes breast tissue during surgical procedure to determine the malignancy status of tumor margins throughout breast cancer surgery. More...


The Dune MarginProbe is an intraoperative, real-time, radiofrequency (RF) spectroscopy system that assists surgeons to positively detect tumor margins. The system is comprised of a sterile, disposable, hand-held probe and a portable console. When the probe tip is applied to an excised lumpectomy segment, RF signals are transmitted into the tissue and reflected back to the console, where they are analyzed using a specialized algorithm to determine tissue status. The system does not require any contrast agents or assistance from a radiologist or a pathologist. Each measurement performed by the MarginProbe scans a coin-shaped volume of tissue 7 mm wide by 1 mm deep. The streamlined operation and the ability to receive instantaneous results are designed to help with an easy integration into the existing surgical workflow. A recent study involving a 300-patient, prospective, randomized, controlled clinical trial of the MarginProbe compared surgeons' ability to detect and remove positive margins during an initial lumpectomy and the resulting reduced rate of repeat procedures. In the MarginProbe group, surgeons applied the probe to the excised lumpectomy specimen and shaved additional tissue according to the device's readings, resulting in a 56% reduction in repeat lumpectomies. The study was published in the October 2008 issue of The American Journal of Surgery.

The MarginProbe is a product of Dune Medical Devices (Caesarea, Israel), which has recently received an investigational device exemption (IDE) approval from the U.S. Food and Drug Administration (FDA). Dune will be launching a clinical trial of the MarginProbe in the United States, which will involve more than 600 women in over a dozen leading medical centers in New York City, Baltimore, Washington DC, Allentown, and Los Angeles.

"Based on the strength of our ongoing studies and their validation of the benefits of MarginProbe, we look forward to the device's acceptance within the surgical community,” said Dr. Dan Hashimshony, founder and CEO of Dune Medical Devices. "Soon thereafter, we hope to help ease the difficulties experienced by women who receive multiple surgeries for breast cancer.”

Related Links:

Dune Medical Devices


Gold Member
Blood Gas Analyzer
i-Check200
Radiology Monitor
MDNC-6121 Barco Nio Color 5.8MP
Rapid Sepsis Test
SeptiCyte RAPID
Patient Monitoring System
AlarmSense
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Artificial Intelligence

view channel
Image: Clinical LLM Performance Improves by >300% When Provided with High-Quality Real-World Evidence in New Precision Medicine Benchmark (Photo courtesy of Atropos Health)

New Benchmark Highlights Evidence Gaps in AI Responses to Clinical Questions

Many clinical decisions still rely on limited evidence, while most artificial intelligence benchmarks overlook the patient context that shapes real-world care. General large language models can also struggle... Read more

Critical Care

view channel
Image Credit: Adobe Stock

New ECG Foundation Model Enables Broad Cardiac Diagnosis and Risk Prediction

Electrocardiograms are central to cardiovascular decision-making, but conventional artificial intelligence models are often trained for narrow tasks, such as detecting a single arrhythmia.... Read more

Point of Care

view channel
Image Credit: 123RF

Continuous Glucose Monitoring Identifies Cardiometabolic Risk in Adults Without Diabetes

Dysglycemia—abnormal blood glucose regulation—can fluctuate throughout the day and often escape conventional screening. Clinicians typically rely on fasting plasma glucose and hemoglobin A1c, which offer... Read more

Business

view channel
Image: LigaSure RAS Maryland, designed for the Valleylab FT10 platform on Hugo RAS, seals and cuts vessels, tissue, and lymphatics up to 7 mm in diameter (Photo courtesy of Medtronic)

Medtronic Receives FDA Clearance for Vessel-Sealing Instrument for Robotic Surgery

As robotic-assisted surgery expands across U.S. hospitals, teams increasingly seek energy instruments with the familiarity and performance of tools used in open and laparoscopic procedures.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.